Carnitine palmitoyltransferase I deficiency
Senast uppdaterad 17 Mar 2025
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
Carnitine palmitoyltransferase I (CPT I) deficiency is a condition that prevents the body from using certain fats for energy.
Videoval för Genetiska tillståndVideobibliotek
Beskrivning
Carnitine palmitoyltransferase I (CPT I) deficiency is a condition that prevents the body from using certain fats for energy.
The signs and symptoms of CPT I deficiency are often brought on by episodes of increased energy demands in the body such as illness or periods of fasting. During these times, affected individuals usually develop low levels of glucose in the blood and a low level of ketones, which are normally produced when fats are broken down to be used for energy. Together, these signs are called hypoketotic hypoglycemia. This may cause individuals to experience confusion, seizures, or a lack of energy (lethargy).
People with CPT I deficiency can also develop an enlarged liver (hepatomegaly) that is not able to remove toxins from the blood efficiently. These toxins build up and can affect brain function (hepatic encephalopathy). As long as no brain damage occurs during these episodes of hepatic encephalopathy, individuals with CPT I deficiency often have normal development.
Health can decline quickly in people with CPT I deficiency. Affected individuals are encouraged to avoid prolonged fasting to prevent serious health problems. Individuals with CPT I deficiency are at risk for nervous system damage, liver failure, coma, and sudden death. These problems can begin any time between infancy to adulthood, though some individuals experience no health problems at all.
CPT I deficiency is often detected shortly after birth by newborn screening, which identifies abnormal levels of certain compounds in the blood. People with CPT I deficiency have high levels of a compound called carnitine. Cells use carnitine, a natural substance that is acquired mostly through the diet, to process fats and produce energy.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Carnitine palmitoyltransferase IA deficiency
CPT 1A deficiency
CPT deficiency, hepatic, type I
CPT I deficiency
Hepatic CPT deficiency
Hepatic CPT1
L-CPT1 deficiency
Liver form of carnitine palmitoyltransferase deficiency
Nonketotic hypoglycemia
Related patient information and medicines

Patient information leaflet
Gastrointestinal malabsorption
Gastrointestinal malabsorption syndrome means a failure to fully absorb digested foods from the gut (bowel) into your body. There are many different causes. Prolonged intestinal malabsorption may cause problems because of a lack of carbohydrates, proteins, fats, minerals and vitamins that are essential to keep you healthy. The treatment will.

Patient information leaflet
Kan jag ta B-vitaminkomplex och C-vitamin tillsammans?
It is best to take your vitamins with water rather than tea or coffee. Using other medicines Taking multiple medicines. Our Interaktionskontroll för läkemedel helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do.

Patient information leaflet
Kan jag ta Vitamin B2 och Vitamin C tillsammans?
G6PD-brist If you have a G6PD-brist (a genetic enzyme condition), high doses of vitamin C can cause your red blood cells to break down (haemolysis). Food and drink warnings Alcohol It is best to avoid or str... Using other medicines Taking multiple medicines. Our Interaktionskontroll för läkemedel helps you check whether your prescriptions,.

Patient information leaflet
Makrocytos och makrocytär anemi
Macrocytosis refers to red blood cells which are larger than normal. It does not cause any symptoms in itself. Macrocytosis symptoms You may also find relevant information in our other separate leaflet called What is blood. What is blood. Macrocytosis can exist without anaemia. Macrocytosis itself does not cause any symptoms but can be a sign of.

Patient information leaflet
Kan jag ta svart cohosh och folsyra tillsammans?
Why t... Black cohosh is primarily broken down by liver enzymes (specifically the CYP450 system), while folsyra is a water-soluble B vitamin that follows a separate metabolic route. They do not interfere with each other's absorption or effectiveness. Vitamin B12 deficiency (Pernicious anaemia) Folic acid can mask the symptoms of a Vitamin B12.

Patient information leaflet
Kan jag ta Vitamin B12 och Vitamin C tillsammans?
Using other medicines Taking multiple medicines. Our Interaktionskontroll för läkemedel helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe till take together. Simply search for your medicines to see potential interactions and what to do about them. Disclaimer This information is for general educational.
Vidare läsning och referenser
- Carnitine palmitoyltransferase I deficiency; MedlinePlus, National Library of Medicine.
- Balci MC, Karaca M, Selamioglu A, Korbeyli HK, Durmus A, Ak B, Kozanoglu T, Gokcay GF. A different perspective into clinical symptoms in CPT I deficiency. Mol Genet Metab Rep. 2023 Nov 30;38:101032. doi: 10.1016/j.ymgmr.2023.101032. eCollection 2024 Mar.
- Bennett MJ, Boriack RL, Narayan S, Rutledge SL, Raff ML. Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. Mol Genet Metab. 2004 May;82(1):59-63. doi: 10.1016/j.ymgme.2004.02.004.
- Gobin S, Thuillier L, Jogl G, Faye A, Tong L, Chi M, Bonnefont JP, Girard J, Prip-Buus C. Functional and structural basis of carnitine palmitoyltransferase 1A deficiency. J Biol Chem. 2003 Dec 12;278(50):50428-34. doi: 10.1074/jbc.M310130200. Epub 2003 Sep 29.
- Lee K, Pritchard A, Ahmad A. Carnitine Palmitoyltransferase 1A Deficiency. 2005 Jul 27 [updated 2025 Feb 20]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1527/
- Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):77-85. doi: 10.1002/ajmg.c.30087.
- Olpin SE, Allen J, Bonham JR, Clark S, Clayton PT, Calvin J, Downing M, Ives K, Jones S, Manning NJ, Pollitt RJ, Standing SJ, Tanner MS. Features of carnitine palmitoyltransferase type I deficiency. J Inherit Metab Dis. 2001 Feb;24(1):35-42. doi: 10.1023/a:1005694320063.
- Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020 Aug;26(7 Suppl):S147-S154. doi: 10.37765/ajmc.2020.88480.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
17 Mar 2025 | Senaste versionen
1 Mar 2025 | Ursprungligen publicerad
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.

